Development of HPLC methodology for quantification of naltrexone and 6β-naltrexol in human plasma and its potential in alcohol use disorder treatment monitoring

Bozmaoglu, C. H., Tok, K. C., Danisman, M., Suzen, H. S., & Gumustas, M. (2025). Development of HPLC methodology for quantification of naltrexone and 6β-naltrexol in human plasma and its potential in alcohol use disorder treatment monitoring. Journal of Pharmaceutical and Biomedical Analysis, 263, 116944. https://doi.org/10.1016/j.jpba.2025.116944

Bozmaoglu CH, Tok KC, Danisman M, Suzen HS, Gumustas M. Development of HPLC methodology for quantification of naltrexone and 6β-naltrexol in human plasma and its potential in alcohol use disorder treatment monitoring. Journal of Pharmaceutical and Biomedical Analysis. 2025;263:116944. doi:10.1016/j.jpba.2025.116944

Bozmaoglu, Ceren H., Kenan Can Tok, Mustafa Danisman, H. Sinan Suzen, and Mehmet Gumustas. 2025. “Development of HPLC methodology for quantification of naltrexone and 6β-naltrexol in human plasma and its potential in alcohol use disorder treatment monitoring.” Journal of Pharmaceutical and Biomedical Analysis 263: 116944. https://doi.org/10.1016/j.jpba.2025.116944.

Bozmaoglu, Ceren H., et al. “Development of HPLC methodology for quantification of naltrexone and 6β-naltrexol in human plasma and its potential in alcohol use disorder treatment monitoring.” Journal of Pharmaceutical and Biomedical Analysis, vol. 263, 2025, p. 116944. https://doi.org/10.1016/j.jpba.2025.116944.

Bozmaoglu, C.H., Tok, K.C., Danisman, M., Suzen, H.S. and Gumustas, M. (2025) ‘Development of HPLC methodology for quantification of naltrexone and 6β-naltrexol in human plasma and its potential in alcohol use disorder treatment monitoring’, Journal of Pharmaceutical and Biomedical Analysis, 263, p. 116944. doi:10.1016/j.jpba.2025.116944.